Rosen Law Firm has filed a securities class action lawsuit against Capricor Therapeutics on behalf of investors who purchased shares between December 17, 2025 and July 26, 2026. The suit alleges that the company made materially false and misleading statements and failed to disclose that it adopted changes to the pre-specified statistical analysis plan for Deramiocel without prior FDA agreement, creating a significant risk that the agency could find the clinical results insufficient to support effectiveness and deny regulatory approval for Duchenne muscular dystrophy. Investors who wish to serve as lead plaintiff must move the Court no later than September 28, 2026. The Rosen Law Firm notes that it has achieved the largest ever securities class action settlement against a Chinese company and was ranked number one by ISS Securities Class Action Services for number of settlements in 2017.
Capricor Therapeutics IncSecurities class action lawsuit alleges false statements and undisclosed changes to statistical analysis plan, risking FDA denial of Deramiocel approval.
